Therapeutic Area Market Research Reports & Industry Analysis
Therapeutic areas include Cardiology/Vascular Diseases, Dental and Oral Health, Dermatology, Devices, Endocrinology, Family Medicine, Gastroenterology, Genetic Disease, Healthy Volunteers, Hematology, Hepatology, Immunology, Infections and Infectious Diseases, Internal Medicine, Musculoskeletal, Nephrology, Neurology, Nutrition and Weight Loss, Obstetrics/Gynecology, Oncology, Ophthalmology, Orthopedics/Orthopedic Surgery, Otolaryngology, Pediatrics/Neonatology, Pharmacology/Toxicology, Podiatry, Psychiatry/Psychology, Pulmonary/Respiratory Diseases, Rheumatology, Sleep, Trauma, Urology, and Vaccines.
Reports in these categories will contain statistics of prevalence and growth concerning therapeutic area diseases for which there are product reviews, market size, and share for products that are used in pharmaceutical treatment or equipment that used in surgical treatment of the therapeutic area.
Therapeutic Area Industry Research & Market Reports
-
Cholesterol Testing
... CAGR of 4.4% over the analysis period 2024-2030. Diagnostic Centers End-Use, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$11.6 Billion by the end of the ... Read More
-
Gastrointestinal (GI) Endoscopy Devices
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$25.5 ... Read More
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Dental Infection Control Products
... 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Dental Infection Control Consumables, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$1.3 Billion ... Read More
-
Neuromodulation
... 9.2% over the analysis period 2024-2030. Spinal Cord Stimulation, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$5.4 Billion by the end of the analysis period. ... Read More
-
Oncology Nutrition
... CAGR of 9.6% over the analysis period 2024-2030. Head & Neck Cancer Nutrition, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$609.6 Million by the end ... Read More
-
Polycystic Ovary Syndrome (PCOS) Treatment
... Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Insulin-Sensitizing Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.3 Billion ... Read More
-
Hip Resurfacing Implants
... at a CAGR of 2.9% over the analysis period 2024-2030. Hybrid Alloy Material, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$128.9 Million by the end ... Read More
-
Assisted Reproductive Technology
... at a CAGR of 4.9% over the analysis period 2024-2030. In-Vitro Fertilization (IVF), one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$22.0 Billion by the end ... Read More
-
Ophthalmic Pharmaceutical Drugs
... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More
-
Idiopathic Pulmonary Fibrosis
... at a CAGR of 5.7% over the analysis period 2024-2030. Pirfenidone, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.8 Billion by the end of the ... Read More
-
Infectious Disease Diagnostics
... at a CAGR of 5.5% over the analysis period 2024-2030. Diagnostic Assays & Reagents, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$25.8 Billion by the ... Read More
-
Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
... expected to reach US$16.4 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 8.3% CAGR ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Orthopedic Surgical Robots
... at a CAGR of 40.2% over the analysis period 2024-2030. Knee Surgery End-Use, one of the segments analyzed in the report, is expected to record a 37.6% CAGR and reach US$6.6 Billion by the end ... Read More
-
Orthopedic Trauma Devices
... at a CAGR of 4.8% over the analysis period 2024-2030. Internal Fixator, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$11.8 Billion by the end of ... Read More
-
Acute Ischemic Stroke Diagnosis and Treatment
... reach US$3.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Computed Tomography Diagnosis, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and ... Read More
-
Artificial Limbs
... CAGR of 4.6% over the analysis period 2024-2030. Upper Extremity Prosthetics, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$925.8 Million by the end of the ... Read More
-
Endometrial Ablation Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$628.5 Million by the end of ... Read More
-
Genitourinary Drugs
... CAGR of 2.3% over the analysis period 2024-2030. Urologicals, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Glaucoma Therapeutics
... CAGR of 3.5% over the analysis period 2024-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.9 Billion by the end of the analysis ... Read More
-
Hospital Acquired Infection Treatment
... 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Urinary Tract Infections, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$31.7 Billion by ... Read More
-
Pigmentation Disorders Treatment
... at a CAGR of 5.7% over the analysis period 2024-2030. Topical Drugs Treatment, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$4.5 Billion by the end ... Read More
-
Rheumatology Therapeutics
... CAGR of 3.2% over the analysis period 2024-2030. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$51.3 Billion by the end ... Read More
Research Assistance
